ReviewOncotarget2018
Value-based genomics.
Review in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.Gynecologic oncology · 2025Trial
- Review
- Mapping the state-of-the-art of the barriers for personalized preventive approaches worldwide: A scoping review of reviews.PloS one · 2025Article
- Development of a microcosting protocol to determine the economic cost of diagnostic genomic testing for rare diseases in Australia.BMJ open · 2023Article
- Article
- ASO Author Reflections: Using Big Data to Bring Precision Medicine to Melanoma Management.Annals of surgical oncology · 2023Article
- A Clinical Decision Tool to Calculate Pretest Probability of Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.Annals of surgical oncology · 2023Article
- Unraveling the genetic architecture of asthma.Annals of translational medicine · 2022Article
- Pyramidal Decision Support Framework Leverages Subspecialty Expertise across Enterprise to Achieve Superior Cancer Outcomes and Personalized, Precision Care Plans.Journal of clinical medicine · 2022Article
- Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers.Nature communications · 2022Article
- Utilisation of semiconductor sequencing for detection of actionable fusions in solid tumours.PloS one · 2022Article
- Whole genome sequencing in oncology: using scenario drafting to explore future developments.BMC cancer · 2021Review
- Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTraOncotarget · 2021Article
- Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer.JCO oncology practice · 2021Article
- Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection.OncoTargets and therapy · 2021Review
- TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.Cancer gene therapy · 2020Review
- Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies.Journal of clinical medicine · 2020Review
- Homologous Recombination Repair Truncations Predict Hypermutation in Microsatellite Stable Colorectal and Endometrial Tumors.Clinical and translational gastroenterology · 2020Article
- The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas.Acta neuropathologica communications · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Advancements in next-generation sequencing have greatly enhanced the development of biomarker-driven cancer therapies. The affordability and availability of next-generation sequencers have allowed for the commercialization of next-generation sequencing platforms that have found widespread use for clinical-decision making and research purposes. Despite the greater availability of tumor molecular profiling by next-generation sequencing at our doorsteps, the achievement of value-based care, or improving patient outcomes while reducing overall costs or risks, in the era of precision oncology remains a looming challenge. In this review, we highlight available data through a pre-established and conceptualized framework for evaluating value-based medicine to assess the cost (efficiency), clinical benefit (effectiveness), and toxicity (safety) of genomic profiling in cancer care. We also provide perspectives on future directions of next-generation sequencing from targeted panels to whole-exome or whole-genome sequencing and describe potential strategies needed to attain value-based genomics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.